50-155-7721
LATS1 Rabbit anti-Human, Mouse, Polyclonal, Bethyl Laboratories
Manufacturer: Bethyl Laboratories, Inc
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-155-7721-Each-of-1 | In Stock | ₹ 43,546.81 |
50-155-7721 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 43,546.81
GST (18%): ₹ 7,838.426
Total Price: ₹ 51,385.236
Antigen
LATS1
Classification
Polyclonal
Conjugate
Unconjugated
Gene
LATS1
Gene Alias
LATS (large tumor suppressor, Drosophila) homolog 1; WARTS protein kinase; h-warts; large tumor suppressor homolog 1; serine/threonine-protein kinase LATS1
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
16798, 9113
Content And Storage
4° C
Form
Liquid
Applications
Immunoprecipitation, Western Blot
Concentration
1 mg/ml
Formulation
phosphate, tris citrate with 0.09% sodium azide; pH 7-8
Gene Accession No.
O95835, Q8BYR2
Gene Symbols
LATS1
Immunogen
Between 1075 and C-term
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse
Product Type
Antibody
Isotype
IgG
Related Products
Description
- The recommended shelf life for this product is 1 year from date of receipt
- LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis
- The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase
- The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A
- In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding
- Biochemical and genetic data suggest a role as a tumor suppressor
- This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.